ImmunoPrecise Antibodies Ltd. (IPA) Price-to-Projected Revenue Ratio
ImmunoPrecise Antibodies (IPA) develops therapeutic antibodies using AI, bypassing traditional laboratories through digital screening. The forward P/S multiple reflects the market consensus trend, and 5.40 is currently becoming the new value for this metric. A strong team of engineers in Europe and Canada ensures research quality, while the deep integration of AI platforms into B2B protocols guarantees high customer loyalty.
Metric breakdowns and analytics for immunoprecise.com (IPA)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital ImmunoPrecise Antibodies|IPA - Long-Term Debt to Capital|Short-Term Debt to Equity ImmunoPrecise Antibodies Ltd.|IPA - Company Aggregate Debt|Debt to Book Value ImmunoPrecise Antibodies Ltd.|IPA - Amount of Long-Term Liabilities|Company Short-Term Debts ImmunoPrecise Antibodies|Quick Ratio immunoprecise.com
- financial results and valuation multiples details:
IPA - Company Net Income|Expected Profit ImmunoPrecise Antibodies|IPA - Market Cap to Earnings|Forward P/E Multiple ImmunoPrecise Antibodies Ltd.|IPA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd.|IPA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) ImmunoPrecise Antibodies|IPA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months immunoprecise.com|IPA - Expected net earnings per share growth this year|Earnings growth forecast for next year ImmunoPrecise Antibodies
- revenue and sales details:
Fundamental company valuation:ImmunoPrecise (IPA)
High R&D expenditures coupled with a deficit in operating cash flow at ImmunoPrecise Antibodies (IPA) make the company's expected P/S chart a key tool for assessing market expectations. The current value of 5.40 reflects the ratio of market capitalization to projected revenue, allowing for a determination of the degree of business undervaluation or the risk of overpaying for future sales amid a cash gap.
Competing companies
Forward P/S Multiple TEM (Tempus AI, Inc.)|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|IONS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Repligen Inc. RGEN|RNA: Forward P/S Multiple|Market Cap to Future Revenue Ratio crisprtx.com (CRSP)|Forward Price-to-Revenue Multiple WGS|RARE: Forward Price to Sales|Forward P/S Multiple BEAM|Forward P/S Multiple Sarepta Corp (SRPT)|Price-to-Projected Revenue Ratio Twist Bioscience TWST|TXG: Market Cap to Projected Revenue|NTLA: Forward Price-to-Revenue Multiple|Stoke Therapeutics Inc - Price to Expected Revenue Ratio|BLFS: Forward P/S Multiple|WVE - Market Cap to Expected Sales Ratio|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SION|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|TSHA - Market Cap to Future Revenue Ratio|Forward P/S Multiple QURE (uniQure Corp)|MGTX: Market Cap to Projected Revenue|REGENXBIO Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio solidbio.com SLDB|OCGN: Forward P/S Multiple|Market Cap to Future Revenue Ratio Pacific Biosciences of California, Inc. (PACB)|Price-to-Projected Revenue Ratio Benitec|Design Corp (DSGN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple RCKT|Market Cap to Expected Sales Ratio 4dmoleculartherapeutics.com|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|KRRO (Korro Bio Inc.) - Future Price to Revenue|Editas - Forward P/S Multiple|SLN - Forward P/S Multiple|PRQR: Forward P/S Multiple|Market Cap to Projected Revenue CDXS|Price-to-Projected Revenue Ratio Sangamo Therapeutics, Inc.|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology Inc)|Forward P/S Multiple MGX|Forward P/S Multiple Precision BioSciences Inc. (DTIL)|Forward P/S Multiple GBIO (Generation Bio)|Market Cap to Expected Sales Ratio boundlessbio.com (BOLD)|XCUR - Price-to-Projected Revenue Ratio|Imunon, Inc. (IMNN) - Forward Price-to-Revenue Multiple|phiopharma.com (PHIO) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Mustang Bio|Forward Price-to-Revenue Multiple RNAZ|Forward P/S Multiple Bionano|Price-to-Projected Revenue Ratio Applied DNA Sciences, Inc. (APDN)|bluebird bio Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega OMGA|Singular Genomics Corp (OMIC) - Market Cap to Future Revenue Ratio|RGLS - Price-to-Projected Revenue Ratio|Future Price to Revenue SYRS|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|TRACON Pharmaceuticals Inc. - Forward Price to Sales|UBX (Unity Bio) - Forward P/S Multiple
